IP Library Granted Patent US 8,247,440
Granted Patent B2
US 8,247,440 · App. 12/389,243 · Granted Aug 21, 2012

Composition comprising omeprazole, lansoprazole and at least one buffering agent

Assignee: Curators of the University of Missouri
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,247,440
App. No.
12/389,243
Granted
Aug 21, 2012
Kind
B2
Abstract

The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and at least one buffering agent.

Claims (17)

1. A pharmaceutical composition comprising omeprazole in an amount of about 60 mg to about 140 mg, lansoprazole in an amount of amount of about 60 mg to about 140 mg, and at least one buffering agent in an amount of about 100 mg to about 4000 mg.

2. The composition of claim 1 , wherein the at least one buffering agent is selected from the group consisting of: sodium bicarbonate, calcium carbonate, calcium formate, magnesium hydroxide, aluminum, aluminum hydroxide/magnesium hydroxide co-precipitate, aluminum hydroxide/sodium bicarbonate co-precipitate, calcium acetate, calcium bicarbonate, calcium borate, calcium bicarbonate, calcium citrate, calcium gluconate, calcium glycerophosphate, calcium hydroxide, calcium lactate, calcium phthalate, calcium phosphates, calcium succinate, calcium tartrate, calcium propionate, dibasic sodium phosphate, dipotassium hydrogen phosphate, dipotassium phosphate, disodium hydrogen phosphate, disodium succinate, dry aluminum hydroxide gel, L-arginine, magnesium acetate, magnesium aluminate, magnesium borate, magnesium bicarbonate, magnesium carbonate, magnesium citrate, magnesium gluconate, magnesium lactate, magnesium metasilicate aluminate, magnesium oxide, magnesium phthalate, magnesium phosphate, magnesium silicate, magnesium succinate, magnesium tartrate, potassium acetate, potassium carbonate, potassium bicarbonate, potassium borate, potassium citrate, potassium metaphosphate, potassium phthalate, potassium phosphate, potassium polyphosphate, potassium pyrophosphate, potassium succinate, potassium tartrate, sodium acetate, sodium borate, sodium carbonate, sodium citrate, sodium gluconate, sodium hydrogen phosphate, sodium hydroxide, sodium lactate, sodium phthalate, sodium phosphate, sodium polyphosphate, sodium pyrophosphate, sodium sesquicarbonate, sodium succinate, sodium tartrate, sodium tripolyphosphate, synthetic hydrotalcite, tetrapotassium pyrophosphate, tetrasodium pyrophosphate, tripotassium phosphate, trisodium phosphate, trometamol, and mixtures of the foregoing.

3. The composition of claim 1 , wherein the at least one buffering agent comprises calcium carbonate and is present in an amount of about 400 mg to about 2500 mg.

4. The composition of claim 1 , wherein the at least one buffering agent comprises calcium formate and is present in an amount of about 400 mg to about 2500 mg.

5. The composition of claim 1 , wherein the at least one buffering agent comprises calcium carbonate and calcium formate.

6. The composition of claim 5 , wherein the calcium carbonate is present in an amount of about 300 mg to about 3000 mg and the calcium formate is present in an amount of about 100 mg to about 4000 mg.

7. The composition of claim 1 , further comprising one or more pharmaceutically acceptable excipients.

8. The composition of claim 7 , wherein the one or more pharmaceutically acceptable excipient is selected from the group consisting of: diluents, disintegrants, binding agents, adhesives, wetting agents, lubricants, glidants, surface modifying agents, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition.

9. The composition of claim 8 , wherein the disintegrant is selected from the group consisting of: croscarnnellose sodium and sodium carboxymethylcellulose.

10. The composition of claim 8 , wherein the lubricant is magnesium stearate.

11. The composition of claim 1 , wherein the composition is in a solid dosage form selected from the group consisting of: tablets, caplets, capsules, powder, lozenges, sachets, cachets, troches, pellets, and granules.

12. The composition of claim 1 , wherein the lansoprazole is present in an amount of about 50 mg to about 150 mg.

13. The composition of claim 1 , wherein the omeprazole is present in an amount of about 70 mg to about 100 mg and the lansoprazole is present in an amount of about 70 mg to about 100 mg.

14. The composition of claim 1 wherein the omeprazole is present in an amount of about 70 mg to about 100 mg and the lansoprazole is present in an amount of about 70 mg to about 100 mg.

15. The composition of claim 1 , wherein the buffering agent comprises sodium bicarbonate.

16. The composition of claim 1 wherein the buffering agent comprises sodium bicarbonate, calcium carbonate and/or calcium formate.

17. The composition of claim 16 , wherein the composition is in a solid dosage form selected from the group consisting of: tablets, caplets, capsules, powder, lozenges, sachets, cachets, troches, pellets, and granules.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2011
From: PHILLIPS, JEFFREY O
To: THE CURATORS OF THE UNIVERSITY OF MISSOURI
Reel/Frame 025800/0047 →
Continuity (2)
Provisional Application 61030045 · Feb 20, 2008
Related Publication 20100130542A1 · May 27, 2010